FCF YoY
+15.42%
OCF YoY
+15.33%
Capex Change
-52.0K
FCF Conversion Δ
—
Free cash flow bridge for Ovid Therapeutics (OVID) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: $7.65M
FCF bridge breakdown for Ovid Therapeutics (OVID) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | −$49.60M | — |
| Operating Cash Flow | $7.60M | +99.3% |
| Capital Expenditure | $52.00K | +0.7% |
| Free Cash Outflow | −$41.95M | — |
- Prior Free Cash Flow−$49.60M
- Operating Cash Flow$7.60M
- Capital Expenditure$52.00K
- Free Cash Outflow−$41.95M
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement